David Ghez

2.8k total citations
81 papers, 1.4k citations indexed

About

David Ghez is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, David Ghez has authored 81 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 34 papers in Pathology and Forensic Medicine and 24 papers in Hematology. Recurrent topics in David Ghez's work include Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Multiple Myeloma Research and Treatments (11 papers). David Ghez is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Multiple Myeloma Research and Treatments (11 papers). David Ghez collaborates with scholars based in France, United States and Canada. David Ghez's co-authors include Olivier Hermine, Yves Lepelletier, Claudine Pique, Ali Bazarbachi, Alina Danu, Vincent Ribrag, Hugues de Thé, Ronan Le Calloch, Rihab Nasr and Bertrand Arnulf and has published in prestigious journals such as Blood, Annals of Internal Medicine and Journal of Virology.

In The Last Decade

David Ghez

75 papers receiving 1.4k citations

Peers

Countries citing papers authored by David Ghez

Since Specialization

Citations

This map shows the geographic impact of David Ghez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ghez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ghez more than expected).

Fields of papers citing papers by David Ghez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ghez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ghez. The network helps show where David Ghez may publish in the future.

Co-authorship network of co-authors of David Ghez

This figure shows the co-authorship network connecting the top 25 collaborators of David Ghez. A scholar is included among the top collaborators of David Ghez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ghez. David Ghez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis 2025 ·eJHaem ·Thomas Hueso, Grégory Lazarian, (unknown), Adrien Chauchet, Ramy Rahmé, Sabine Bréchignac, Vincent Lévy, Salomon Manier, Damien Roos‐Weil, David Ghez, Claude Gardin, Fanny Baran‐Marszak, Éric Durot, Pierre Morel, Thorsten Braun	0
2	Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm 2024 ·Blood Advances ·(unknown), Arnaud Pagès, (unknown), (unknown), Rudy Birsen, (unknown), Adrien Contejean, Alina Danu, Stéphane de Botton, (unknown), Pierre‐Yves Dumas, Arnaud Jaccard, Anne Marfaing‐Koka, Christophe Willekens, Éric Deconinck, David Ghez	2
3	Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases 2023 ·Cancer/Radiothérapie ·(unknown), (unknown), Julien Lazarovici, Alina Danu, David Ghez, Khalil Saleh, (unknown), (unknown), (unknown), (unknown), (unknown), Jean‐Marie Michot, (unknown)	1
4	Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma 2021 ·Cancer Drug Resistance ·Jean‐Marie Michot, (unknown), Maxime Annereau, (unknown), Alina Danu, Clémentine Sarkozy, Claude Chahine, Camille Bigenwald, Jacques Bosq, Julien Rossignol, (unknown), Capucine Baldini, David Ghez, Peggy Dartigues, Christophe Massard, Vincent Ribrag	3
5	Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients 2020 ·Blood Advances ·Kamel Laribi, Alix Baugier de Materre, Mohamad Sobh, Lorenzo Cerroni, Caterina Giovanna Valentini, Tomohiro Aoki, Ritsuro Suzuki, Kengo Takeuchi, Arthur E. Frankel, Carlo Cota, David Ghez, Ronan Le Calloch, Livio Pagano, Tony Petrella	41
6	66P High incidence of TP53 and epigenetic modifying oncogene mutations in a large cohort of patients enrolled in phase I clinical trials for R/R DLBCL 2020 ·Annals of Oncology ·Cyril Quivoron, Jean‐Marie Michot, Valérie Camara‐Clayette, Alina Danu, (unknown), Clémentine Sarkozy, David Ghez, Julien Rossignol, Capucine Baldini, P. Martin Romano, Andréa Varga, Sophie Cotteret, Peggy Dartigues, Christophe Massard, Vincent Ribrag	1
7	Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Claude Chahine, Damien Roos‐Weil, Véronique Saada, Stéphane de Botton, Jean‐Baptiste Micol, Stéphane Barète, Christophe Marzac, David Ghez	5
8	Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib 2018 ·Blood ·David Ghez, (unknown), Caroline Protin, Marine Baron, Marie‐Pierre Ledoux, Gandhi Damaj, Mathieu Dupont, Brigitte Dreyfus, Emmanuelle Ferrant, Charles Herbaux, Kamel Laribi, Ronan Le Calloch, Marion Malphettes, Franciane Paul, Laëtitia Souchet, (unknown), K. Delavigne, Caroline Dartigeas, Loïc Ysebaert	205
9	Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy 2017 ·Blood ·(unknown), Jean‐Marie Michot, Julien Lazarovici, Khalil Saleh, David Ghez, Claude Chahine, Loïc Verlingue, Christophe Willekens, Véronique Vergé, Christophe Fermé, Alina Danu, Vincent Ribrag	0
10	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma 2017 ·Blood ·Timothy Brighton, Simon J. Harrison, David Ghez, Brendan M. Weiss, Andreas Kirsch, Hila Magen, Mercedes Gironella, Albert Oriol, Matthew Streetly, Xiang Qin, Rajesh Bandekar, Peter Hu, Ming Qi, (unknown), Hartmut Goldschmidt	5
11	Le lymphome de Hodgkin : stratégies thérapeutiques actuelles et futures 2017 ·Bulletin du Cancer ·Anthony Turpin, Jean‐Marie Michot, Emmanuelle Kempf, R. Mazeron, Peggy Dartigues, M. Terroir, (unknown), (unknown), Cristina Castilla‐Llorente, Téreza Coman, Alina Danu, David Ghez, Sylvain Pilorge, Julia Arfi‐Rouche, Laurent Dercle, Jean‐Charles Soria, Patrice Carde, Vincent Ribrag, Christophe Fermé, Julien Lazarovici	3
12	Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), M. Terroir, Julia Arfi‐Rouche, Jean‐Marie Michot, Sacha Mussot, (unknown), Maria‐Rosa Ghigna, Peggy Dartigues, (unknown), Alina Danu, Christophe Fermé, Vincent Ribrag, David Ghez	21
13	Challenges and perspectives in the immunotherapy of Hodgkin lymphoma 2017 ·European Journal of Cancer ·Jean‐Marie Michot, Julien Lazarovici, David Ghez, Alina Danu, Christophe Fermé, Amélie Bigorgne, Vincent Ribrag, Aurélien Marabelle, Sandrine Aspeslagh	20
14	Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group 2015 ·Haematologica ·David Sibon, Franck Morschhauser, Matthieu Resche‐Rigon, David Ghez, Jehan Dupuis, Ambroise Marçais, Bénédicte Deau, Réda Bouabdallah, Catherine Sebban, Gilles Salles, Pauline Brice	28
15	Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia 2014 ·Annals of Hematology ·Édouard Cornet, Alain Delmer, Pierre Feugier, Francine Garnache‐Ottou, David Ghez, Véronique Leblond, Vincent Lévy, Frédéric Maloisel, (unknown), Jean‐Marc Zini, Xavier Troussard	34
16	Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis 2013 ·European Journal of Cancer ·David Ghez, Jean‐Baptiste Micol, Florence Pasquier, Nathalie Auger, Véronique Saada, Marc Spentchian, Jean‐Christophe Ianotto, Jean Bourhis, (unknown), Christine Terré, Sylvie Castaigné, Sophie Rigaudeau, Philippe Rousselot, Stéphane de Botton	16
17	Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis 2007 ·Transfusion ·François Lefrère, Sarah Zohar, (unknown), (unknown), Jean‐Antoine Ribeil, David Ghez, Bruno Varet, Marina Cavazzana, Liliane Dal Cortivo, Rémi Letestu, (unknown), Chantal Brouzes	29
18	Reversible paraparesis in multiple myeloma with renal failure 2006 ·Nephrology Dialysis Transplantation ·Benjamin Terrier, Dominique Joly, David Ghez, Bertrand Knebelmann, Fádi Fakhouri, Aurélie Hummel	3
19	New therapeutic approaches for adult T-cell leukaemia 2004 ·The Lancet Oncology ·Ali Bazarbachi, David Ghez, Yves Lepelletier, Rihab Nasr, Hugues de Thé, Marwan El‐Sabban, Olivier Hermine	95
20	Control of a relapse and induction of long-term remission of Wegener's granulomatosis by cyclosporine 2002 ·American Journal of Kidney Diseases ·David Ghez, Pierre‐François Westeel, Isabelle Henry, A Pruna, Albert Fournier, Kaı̈ss Lassoued	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact